Company intelligence / Profile preview

Bacainn Therapeutics, Inc.

Concord, Massachusetts, United Statesbiospace.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Completed Phase 1 trial of BT051 showing it was safe and well-tolerated in healthy subjects at doses up to 3500mg. The drug demonstrated undetectable or minimal systemic exposure with high stool concentrations across all doses. A Phase 1b trial in patients with moderate to severe ulcerative colitis was planned to begin in 2021.

Therapeutic areas: GastroenterologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BT051

Phase 1

Indications: Ulcerative colitis, Inflammatory bowel disease

Partnerships

University of Massachusetts Medical School

Beyond the preview

Go deeper on Bacainn Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacainn Therapeutics, Inc..

Explore the full profile